Roche’s RoACTEMRA monotherapy showed superior improvement in rheumatoid arthritis
2 March 2012 | By Roche
Roche announced preliminary results from the ADACTA study...
List view / Grid view
2 March 2012 | By Roche
Roche announced preliminary results from the ADACTA study...
27 February 2012 | By Roche
Roche has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc. at a price of $44.50 per share...
20 February 2012 | By Roche
First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live significantly longer...
8 February 2012 | By Roche
The U.S. FDA has accepted the company’s Biologics License Application for pertuzumab...
30 January 2012 | By
The first medicine for adults with advanced basal cell carcinoma...
27 January 2012 | By Roche
Roche has commenced a cash tender offer to acquire all outstanding shares of Illumina, Inc....
26 January 2012 | By Roche
Roche has responded to an announcement from Illumina, Inc...
25 January 2012 | By Roche
Roche announced that it is proposing to acquire all outstanding shares of Illumina, Inc...
23 January 2012 | By Roche
Establishment of a program to improve basic cancer care in Ethiopia...
19 December 2011 | By Roche
For the treatment of people with BRAF mutation-positive metastatic melanoma...
15 December 2011 | By Merck
New clinical trial will evaluate an investigational therapeutic regimen with VICTRELIS™ (boceprevir)...
15 December 2011 | By Roche
Roche announced that Sophie Kornowski-Bonnet has been appointed Head of Roche Partnering...
8 December 2011 | By Roche
6.1 month improvement in median progression free survival, from 12.4 to 18.5 months...
1 December 2011 | By Roche
Roche have announced that the cobas EGFR Mutation Test is now CE marked...
30 November 2011 | By Roche
Results from studies to be presented at SABCS...